SecBot SecBot

BIOA drug pipeline

BioAge Labs, Inc. · 1 rated drug
$5.55
−1.8% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 2
Time to marketAt least 3-5 years away. BGE-102 is in Phase 2; even with positive data, Phase 3 trials and FDA review would take several years. The QUELL-DME trial results are not expected until H2 2027.

BGE-102 Updated Nov 9

What to watch

The QUELL-CV Phase 2 topline data, expected in Q4 2026 (any day now through December), is the single most important catalyst. Positive data showing a clear dose-response on hsCRP and cardiometabolic biomarkers would validate BGE-102's best-in-class profile and likely drive a significant stock re-rating given the current depressed valuation. Negative or equivocal data would compound the sector skepticism from Novo Nordisk's failure and could pressure the stock further. QUELL-DME data in H2 2027 is a secondary catalyst.

Bull case
  • Phase 1 data showed 85% median hsCRP reductions, suggesting potential best-in-class oral NLRP3 inhibition
  • Analyst consensus is strongly bullish: 12 Buy-equivalent ratings vs 4 Hold, with a mean price target of $32.56 (510% upside from $5.34)
  • Strong institutional accumulation in Q2 2026: BlackRock, Geode, Goldman Sachs, JPMorgan, and Bank of America all added positions
Bear case
  • Novo Nordisk's disappointing Phase 3 cardiovascular trial results in July 2026 sparked sector-wide skepticism about NLRP3-targeting therapies, causing BIOA stock to plunge
  • BGE-102 is still early-stage (Phase 2) with no proof-of-concept data yet in cardiovascular or retinal disease
  • QUELL-CV topline data could fail to show a clear dose-response or meaningful biomarker improvement